Consumer inSights Q3 2024 shows shifts in eyewear spending: continuing preference for budget options, primarily in-store.

New research sheds light on how the dry eye medication lifitegrast works beyond the ocular surface, targeting the underlying immune system to provide relief for patients.

Dr. Shane Kannarr discusses findings on perfluorohexyloctane at the Tear Film and Ocular Surface conference, highlighting its rapid symptom relief and enhanced patient satisfaction.

Catch up on what happened in optometry during the week of October 28-November 1.

Comfort, vision, freedom from glasses, and convenience were cited as benefits of wearing contact lenses by survey participants.

Optical devices and rehabilitation training can improve a patient’s quality of life.

Dr. Walline shares his journey to the AAOpt presidency, his passion projects, and what’s to come at Academy 2024.

Six topics were assessed in the report, including global data on myopia prevalence, technology, environmental and genetic contributions to myopia onset and progression, and mechanistic causes of myopia pathogenesis, among others.

Higher prevalence rates were also found among university students and administrative workers.

Tips for talking to patients about sun protection.

74% of participants dosed with LNZ100 achieved 3 or more lines of improvement 3 hours post-treatment.

Entering the final lap to 2024 American Academy of Optometry annual meeting.

Understanding and balancing digital exposure in children can reduce myopia progression.

Catch up on what happened in optometry during the week of October 21-October 25.

Dry eye increases susceptibility to psychiatric disorders and chronic pain syndromes, investigators reported at the 2024 American Academy of Ophthalmology meeting.

The data showed a reduction in the GA lesion growth rate of 15.3% versus placebo from 6 to 24 months and a slowing in GA growth rate of 13.4% from baseline to 24 months.